



Corporate office:303, Gold Star

Reg. Office: Office No. 17/B, 4th Floor, Sandesh Commercial Complex, Old Madhuram Cinema, Mirzapur, AHMEDABAD - 380001 Email: bostonsystem@yahoo.com Web: www.bostonbiosystemltd.com

CIN :- L31100GJ1995PLC025476

Date: 07th February, 2018

To. **Department of Corporate Services BSE** Limited, Ground Floor, PJ Towers, **Dalal Street Fort,** Mumbai- 400001.

Scrip Code: 531458

Subject:- Outcome/Results of Meeting of Board of Directors of the Company held on 07th February, 2018

Dear Sir/Madam,

This is to inform you that the 4th/2017-18 meeting of Board of Directors of the **Boston** Bio Systems limited, in their meeting held on 07th February, 2018 (which commenced at 4:00 pm and concluded at 4:30 p.m.) have inter alia considered and approved the Standalone Unaudited Financial Results of the Company, pursuant to the Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, for the quarter ended 31st December, 2017 along with Limited Review Report thereon.

Kindly acknowledge the receipt of the same.

Thanking You.

Yours faithfully,

FOR BOSTON BIO SYSTEMS LIMITED

KUSHAL RATHOR

DIRECTOR DIN: - 06493647

BOSTON BIO SYSTEMS LIMITED 17/B, 4TH FLOOR, SANDESH COMMERCIAL COMPLEX, OLD MADHURAM CINEMA, MIRZAPUR AHMEDABAD Ahmedabad GJ 380001 Statement of Standalone Un-audited Financial Results for the quarter ended 31st December, 2017 (Rs. In Lakhs)

			Quarte	r Ended		Year Ended
Sr .No	Particulars	31.12.2017	30.9.2017	31.12.2017	31.12.2016	31.03.2017
		1.10.2017 to	1.7.2017 to	1.4.2017 to	1.10.2016 to	1.4.2016 to
		31.12.2017	30.9.2017	31.12.2017	31.12.2016	31.3.2017
		Unaudited	Unaudited	Unaudited	Unaudited	Audited
	Income from Operations					
-	•	24.20	22.42	46.04	0.05	40.73
	(a) Revenue from Operations (Net of Excise Duty)	24.38	22.43	46.81	0.05	48.73
II III	(b) Other Income Total Income from Operations (Net)	0.15 24.53	22.43	0.15 46.96	0.05	5.00 53.73
	Total income from Operations (Net)	24.53	22.43	46.96	0.05	55./5
IV	Expenses					
IV	(a) Cost of Material Consuimed	_	_	-	_	_
	(b) Purchase of Stock-in-Trade	25.66	19.98	45.64	0.05	6.28
	(c) Changes in inventories of finished good, work in progress & Stock-in-Trade	(1.75)	15.56	(1.75)	0.03	0.28
	(d) Employee Benefit Expenses	0.24	0.60	0.84	-	0.14
	(e) Finance Cost	-	-	-	-	- 0.14
	(f) Depreciation and Amortisation Expenses	-	-	-	-	0.62
	(g) Other Expenses (Any item exceeding 10% of the total expenses relating to continuing					0.02
	operations to be shown separately)	0.13	1.23	1.36	_	42.28
	i) Power & Fuel	0.13	-	-	-	42.20
	ii) Annual Listing Fees	_	-		_	-
	iii) Custodian Fees					
	iv) Rent	_	-	-	-	-
	v) Penalty Expense		-	_	_	_
	vi) Professional Fees	_	-	-	-	_
	vii) Registrar Fees	_	-	-	-	_
	viii) Other Expense	-	-	-	-	-
	Total Other Expense	-	-	-	-	-
	Total Expenses (IV)	24.28	21.81	46.09	0.05	49.32
V	Profit & Loss From Operations Before Exceptional Item and Tax (III - IV)	0.25	0.62	0.87	-	4.41
VI	Exceptional Items	-	-	-	-	-
VII	Profit & Loss from Ordinary Activites before Tax (V - VI)	0.25	0.62	0.87	-	4.41
VIII	Tax Expenses	-	-	-	-	0.05
IX	Net Profit/(Loss) for the period from Continuing Operations (VII - VIII)	0.25	0.62	0.87	-	4.36
Х	Net Profit/(Loss) for the period from Discontinued Operations	-	-	-	-	-
XI	Tax Expense of Discontinued Operations	-	-	-	-	-
XII	Net Profit/(Loss) from Discontinued Operations after Tax (X - XI)	-	-	-	-	-
	Net Profit/(Loss) for the period (IX + XII)	0.25	0.62	0.87	-	4.36
XIV	Other Comprehensive Income	-	-	1	-	-
A(i)	Items that will not be reclassified to profit or loss	-	-	-	-	-
A(ii)	Income Tax relating to Items that will not be reclassified to profit or loss	-	-	-	-	-
B(i)	Items that will be reclassified to profit or loss	-	-	-	-	-
B(ii)	Income Tax relating to Items that will be reclassified to profit or loss	-	-	-	-	-
XV	Total Comprehensive Income for the period (XIII + XIV) comprising Profit/(Loss) and					
۸۷	other Comprehensive Income for the period.	-	-	-	-	-
XVI	Earning per Equity Share (for continuing operations):					
	(i) Basic	0.04	0.09	0.12	-	0.05
	(ii) Diluted	-	-	-	-	(0.65
XVII	Earning per Equity Share (for discontinuing operations):					
	(i) Basic	-	-	-	-	-
	(ii) Diluted	-	-	-	-	-
	Earning per Equity Share (for continuing and discontinuing operations):					
	(a) Basic	0.04	0.09	0.12	-	0.05
	(b) Diluted	-	-	-	-	(0.65

cwfb fbncwcnnw

Gс

n

n c c

G fb w / w c / w fbn fb fb r /

n c fb n

w fb n fb n g fb r

nc wc wc wn

n

n n y fb w

fb w fb n ffb

c C fb &

 n
 G

 w
 c
 cj
 n
 w
 w
 n
 n
 y
 r

 fb
 w
 fb
 w
 fb
 w
 fb
 w
 fb
 fb

fb n w &n w &fb c w

fb C) c r n

n n fb w N n n C

	fb fb			n w
n	W	C	<u></u>	
			n r nc) fb	n n c) fb
fb/)	W)		
j n	. /)			
fb/)				
n	w n			
n	w n fb			
c C	n c	w fb	n n fb	/ G /G / / c n

For & Behalf of BOSTON BIO SYSTEMS LTD

KUSHAL RATHORE

(Director) DIN: 06493647

CHARTERED ACCOUNTANTS

CA Vishal Nahar

B.Com., F.C.A., DISA (LC.A.L.)

12, Bajaj Khana, JAORA: Dist. Frodati : 07414-221253, 222652 Mob. 98272 73710, Fax: 0731-257794 TE-maii: vrianarin@yahoo.com

Ref

Date:

TO,
THE BOARD OF DIRECTORS
BOSTON BIO SYSTEMS LIMITED
17/B, 4th Floor, Sandesh commercial complex,
Mirzapur court, ahmedabad-380001

SUBJECT: Independent Auditor's Review Report on Quarterly Standalone Financial results for the quarter ended 31st December,2017 of Boston Bio Systems Limited pursuant to Regulation 33 of SEBI (Listing obligation and Disclosure Requirements) Regulations 2015

Dear Sir,

We have reviewed the accompanying statement of Unaudited Standalone Financial Results of **BOSTON****BOSYSTEMS LIMITED ("the Company") for the quarter ended 31⁵ December, 2017 ("the Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July5, 2016. Attention is drawn to the fact that the figures for the corresponding quarter ended 31st December, 2017 including the reconciliation of net profit for the quarter reported under previous GAAP, as reported in these financial results have been approved by the Company's Board of Directors but have not been subjected to review.

This statement is the responsibility of the Company's Management and has approved by the Board of Directors. Our responsibility is to issue a report on these financial readements based on our review.

We conducted our review of the Statement in accordance with the Standard on review Engagement (SRE) 2410" Review of Interim Financial Information Performed by the Independent auditor of the entity." issued by the Institute of Charted Accountants of India . This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review is limited primarily to inquiries of Company Personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.



Nahar V. & Gompany

CHARTERED ACCOUNTANTS

CA Vishal Nahar

B.Com., F.C.A., DISA (I.C.A.I.)

12, Bajaj Khana, JAORA; Dist. Ratlam

2: 07414-221253, 222652

Mob. 98272 73710, Fax: 0731-2577943

E-mail: vnaharin@yahoo.com

Ref.

Date:

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the applicable Indian accounting standards(Ind-AS) as prescribed with the applicable under section 133 of the Companies Act,2013 read with relevant rules issued there under and other recognized accounting practices and principles generally accepted in India, has not disclosed the information required to be disclosed in terms of regulation 33 of SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July5, 2016 including the manner in which it is to be disclosed or that it contains any immaterial mis-statement.

Date: 07/02/2018

Place: Indore



Partner M. NO. 400217 F.R. NO. 010443C